SCAI 2026
High lipoprotein(a) tied to cardiovascular risk, despite standard treatment
Clinical takeaway: Lipoprotein(a) may help identify residual cardiovascular risk that standard treatment doesn't fully address, especially in patients with established heart disease. These findings support measuring lipoprotein(a) at least once and intensifying overall risk reduction when levels are markedly elevated. The highest risk emerged at levels of 175 nmol/L or greater, with the strongest signals for stroke, cardiovascular death, and risk in patients with existing heart disease.
Lipoprotein(a) has long been recognized as an inherited cardiovascular risk factor, but it has been less clear how much risk it carries in treated patients and at what level that risk becomes most clinically meaningful. Elevated lipoprotein(a) is a largely inherited condition that affects about one in five people.
This analysis aimed to identify the threshold associated with the greatest residual risk across patients with and without known heart disease. Researchers analyzed stored plasma samples from 20,070 adults age 40 years and older in three National Institutes of Health trials: ACCORD, PEACE, and SPRINT. Lipoprotein(a) levels were grouped as less than 75, 75 to 125, 125 to 175, or 175 nmol/L or greater, and models were adjusted for demographics, comorbidities, lipid levels, and therapies.
Over a median follow-up of about four years, lipoprotein(a) levels of 175 nmol/L or greater were independently associated with a 31% higher risk of major adverse cardiovascular events, a 49% higher risk of cardiovascular death, and a 64% higher risk of stroke.
The association was stronger in patients with existing heart disease than in those without it, and elevated lipoprotein(a) wasn't linked to higher heart attack risk in this analysis. Lipoprotein(a) doesn’t replace standard risk assessment, but it may identify patients whose residual risk remains high despite otherwise appropriate treatment.
“For the first time, we can quantify the specific level of Lp(a) that puts patients at a significantly higher risk of major cardiovascular events, especially stroke and death,” said Subhash Banerjee, MD, FSCAI, interventional cardiologist at Baylor Scott & White in Dallas, Texas. “Regardless of age, patients can take a simple, low-cost blood test to determine whether they have this genetic condition. If elevated Lp(a) levels are detected, they should work closely with their healthcare provider to aggressively lower LDL cholesterol and manage other cardiovascular risk factors as much as possible.
Source: Banerjee S. SCAI Scientific Sessions 2026. 2026 Apr 24. Lipoprotein(a) Identifies Residual Cardiovascular Risk in NIH Randomized Trials